ADCT

ADC Therapeutics

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NYSE

County of HQ

Switzerland

Next Earnings Date

05/13/26

Business Summary

ADC Therapeutics is a biotechnology company focused on antibody-drug conjugates designed to target and deliver cytotoxic payloads directly to cancer cells. Its model centers on developing and commercializing oncology therapeutics, capturing value through product sales and potential partnerships. The moat, when functioning, lies in proprietary linker technology, targeted biologics expertise, and clinical data that create barriers to replication. Cash generation depends on successful commercialization of approved therapies and advancing pipeline assets through regulatory milestones, where pricing power in oncology can translate into high operating margins.

VALUATION

P/E

-

Market Cap ($M USD)

$475

Forward P/E

-

PEG

-

PRICE TO SALES

5.8

PRICE TO BOOK

-

EV / EBITDA

-3.8

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.12

Next Year EPS Growth Estimate

-$0.64

Next Year Revenue Growth Estimate

68.40%

Return on Equity (ROE)

76.80%

Operating Margin

-131.80%

Debt-to-Equity

-

Piotroski F-Score

4

Altman Z-Score

-6.5

Return on Invested Capital (ROIC)

132.20%%

Current Ratio

4.4

Quick Ratio

Gainseekers Quantitative Analysis

Summary

This is a highly speculative balance sheet wrapped in superficially strong operating metrics. With no P/E or Forward P/E and a deeply negative EPS of -3.8 (improving to an estimated -1.12 next year), traditional valuation anchors are absent, forcing investors to underwrite pure forward optionality. A Price/Sales of 5.8 against a $475M market cap is not cheap for a company with negative earnings and projected Sales Growth Next Year of -$0.64. Most alarming is the Altman Z-Score of -6.5, which signals extreme financial distress risk. The market is not mispricing stability here — it is pricing survival risk.

AI Exposure / Tech Reliance

As a biotechnology company, ADC Therapeutics operates in a sector where AI-driven drug discovery, biomarker analysis, and clinical trial optimization are becoming core competitive tools. The industry’s shift toward data-driven oncology research could enhance pipeline efficiency and capital allocation discipline. However, AI leverage only matters if the company can sustain funding long enough to commercialize its assets.

The Bull Case

A deep value or speculative GARP investor would point to the extraordinary Operating Margin of 76.80% and ROIC of 132.20% as evidence that the underlying asset base can generate significant economic returns when revenue materializes. A Return on Equity of 68.40% suggests capital efficiency on paper, and the Current Ratio of 4.4 indicates strong short-term liquidity relative to liabilities. The Piotroski F-Score of 4 is neutral, not broken, implying operational stability rather than deterioration. With a modest $475M market cap and a Mean Consensus Target Price of 1.43, bulls will argue that asymmetric upside exists if losses narrow toward the projected EPS of -1.12 next year.

The Bear Case

The structural risks are severe. Debt/Equity of -131.80% reflects a deeply impaired equity base, and the Altman Z-Score of -6.5 is a textbook distress signal. EPS remains negative at -3.8, Sales Growth Next Year is projected at -$0.64, and there is no PEG Forward or P/E support to justify growth-based valuation. Institutional Ownership listed at $8.00 suggests limited sponsorship depth, and the absence of profitability combined with a 5.8 Price/Sales multiple leaves little margin for execution error. This is a capital-intensive biotech with shrinking top-line expectations and statistically elevated bankruptcy risk.

Market Sentiment & Smart Money

Short Interest %

4.10%

Analyst Consensus

1.43

Average Analyst Price Target

$8.00

Institutional Ownership %

66.50%

1-Year Beta

1.76

Insider Buying % (6 Mo)

12.90%%

Distance to 52-Week High

75.10%%

Distance to 52-Week Low

340.00%%